Startup · $415m raised
Melbourne, VIC
Every investor coverage indicates participated in a round Synchron raised.
| Investor | Rounds | Invested |
|---|---|---|
| Alumni Ventures | Series C | - |
| Arch Venture Partners | Series C | - |
| ARCH Ventures | Series D+ | - |
| Bezos Expeditions | Series D+ · Series C | - |
| Bill Gates | Series C | - |
| Double Point Ventures | Series D+ | - |
| Forepont Capital | Series C | - |
| Gates Frontier | Series C | - |
| Greenoaks Capital | Series C | - |
| ID8 Investments | Series C | - |
| IQT | Series D+ | - |
| Jeff Bezos | Series C | - |
| K5 Global | Series D+ | - |
| Khosla Ventures | Series D+ · Series C | - |
| METIS | Series D+ · Series C | - |
| Moore Strategic Ventures | Series C | - |
| NeuroTechnology Investors | Series C | - |
| NRF Corporation | Series D+ | $54,000,000 |
| NTI | Series D+ | - |
| Project X | Series C | - |
| Protocol Labs | Series D+ | - |
| Qatar Investment Authority (QIA) | Series D+ | - |
| Reliance Digital Health | Series C | - |
| Shanda Group | Series C | - |
| T.Rx Capital | Series D+ | - |
Investors whose own portfolio pages list Synchron, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Tin Alley Ventures | its portfolio page ↗ |
Companies Synchron acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Synchron. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
An analysis of what happens to brain-implant trial participants once studies end, covering Australia's growing neurotech sector, EpiMinder's FDA approval, Synchron's funding, and recommendations from a convened panel of specialists.
LaunchVic and dealroom.co report Victorian startups raised a record $2.4 billion in 2025, driven by late-stage deals despite early-stage declines.
Roundup of eight funding deals: Synchron's Series D, plus raises by Lumonus AI, Hullbot, Nbryo, Cytophenix, Giftbee, Understanding Zoe and Zeligate, spanning medtech, robotics, agtech and AI.
Also Startup Daily·Startup Daily·Startup Daily·Startup Daily·SmartCompany·Startup Daily·Startup Daily
A rundown of Gartner's ten technology trends to watch in 2025, spanning agentic AI, governance platforms, disinformation security, quantum-safe cryptography, spatial computing, robotics and neurological enhancement, with Australian startup Synchron cited.
Australian neurotech firm Synchron reported year-long trial results showing its brain implant was safe in six US patients, including one who used Amazon's Alexa by thought alone, keeping it ahead of Musk's Neuralink.
Analysis of Neuralink's first human implant, its clinical and ethical challenges, and the competitive threat posed by Melbourne brain-computer interface startup Synchron.
MedTech Actuator alumni are behind Synthesis Capital, a new venture fund courting investors for up to $100m to back young health technology companies across Australia and the Asia-Pacific.
An overview of brain-computer interface history and current clinical-trial leaders, profiling BrainGate, a Dutch medical centre, and Melbourne-founded Synchron, written by a University of Melbourne neural engineering academic.
Analysis of the technological singularity concept, covering brain-computer interface work by Neuralink and Synchron, expert predictions about artificial general intelligence, and worries over unregulated AI. Republished from The Conversation.
Techboard's monthly roundup catalogues December 2022 startup raises, led by Synchron's $110m Series C, with health and biotech taking the largest share and 55 funding events captured totalling $546m.
Weekly roundup covering 14 startup raises totalling over $260 million, headlined by Synchron's $110 million round, plus Roller's shareholder liquidity payout, Partly's record New Zealand Series A, and several government grants.
Also GrainCorp Ventures·SmartCompany·Startup Daily·SmartCompany·@AuManufacturing·SmartCompany·Startup Daily·Startup Daily·Techboard·SmartCompany·SmartCompany·SmartCompany·SmartCompany·Startup Daily·SmartCompany·Startup Daily·@AuManufacturing·Startup News (WA)·Startup News (WA)
Brain-computer interface maker Synchron has closed an oversubscribed Series C, with proceeds earmarked for product development and clinical trials; its co-founder downplays any rivalry with Neuralink.
Also Startup Daily·SmartCompany·@AuManufacturing·Techboard·Startup Daily
Australian neurotech firm Synchron has implanted its brain-computer device in a US patient, reportedly ahead of Neuralink, which has seen several founders, including Max Hodak and Paul Merolla, depart.